Published by Iain Gilbert on 8th April 2026
(Sharecast News) - Drugmaker GSK said on Wednesday that China's National Medical Products Administration has approved Exdensur as an add‑on therapy with intranasal corticosteroids for adults with chronic rhinosinusitis with nasal polyps who do not achieve adequate control with systemic steroids or surgery.